Magnesium sulfate administration — Competitive Intelligence Brief

Magnesium sulfate administration (Magnesium sulfate administration) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Electrolyte/mineral supplement; anticonvulsant. Area: Obstetrics; Neurology; Cardiovascular.

marketed Electrolyte/mineral supplement; anticonvulsant NMDA receptor; L-type calcium channel Obstetrics; Neurology; Cardiovascular Small molecule

Target snapshot

Magnesium sulfate administration (Magnesium sulfate administration) — University of California, San Francisco. Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Magnesium sulfate administration TARGET	Magnesium sulfate administration	University of California, San Francisco	marketed	Electrolyte/mineral supplement; anticonvulsant	NMDA receptor; L-type calcium channel
Magnesium sulfate 24 hours	Magnesium sulfate 24 hours	Instituto Materno Infantil Prof. Fernando Figueira	marketed	NMDA receptor antagonist; tocolytic agent; anticonvulsant	NMDA receptor; L-type calcium channels
Intravenous magnesium sulfate infusion	Intravenous magnesium sulfate infusion	Chinese University of Hong Kong	phase 3	Electrolyte/mineral supplement; anticonvulsant; vasodilator	NMDA receptor; L-type calcium channel
Balance Tablet	Balance Tablet	General Committee of Teaching Hospitals and Institutes, Egypt	marketed	Electrolyte/mineral supplement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Electrolyte/mineral supplement; anticonvulsant class)

1. University of California, San Francisco · 1 drug in this class